Discovery of Pyrrolopyridine−Pyridone Based Inhibitors of Met Kinase: Synthesis, X-ray Crystallographic Analysis, and Biological Activities

Kyoung Soon Kim(Bristol-Myers Squibb (United States)), Liping Zhang(Bristol-Myers Squibb (United States)), Robert J. Schmidt(Bristol-Myers Squibb (United States)), Zhen‐Wei Cai(Bristol-Myers Squibb (United States)), Donna Wei(Bristol-Myers Squibb (United States)), David Williams(Bristol-Myers Squibb (United States)), Louis J. Lombardo(Bristol-Myers Squibb (United States)), George L. Trainor(Bristol-Myers Squibb (United States)), Dianlin Xie(Bristol-Myers Squibb (United States)), Yaquan Zhang(Bristol-Myers Squibb (United States)), Yongmi An(Bristol-Myers Squibb (United States)), John S. Sack(Bristol-Myers Squibb (United States)), John S. Tokarski(Bristol-Myers Squibb (United States)), Celia D’Arienzo(Bristol-Myers Squibb (United States)), Amrita V. Kamath(Bristol-Myers Squibb (United States)), Punit Marathe(Bristol-Myers Squibb (United States)), Yueping Zhang(Bristol-Myers Squibb (United States)), Jonathan Lippy(Bristol-Myers Squibb (United States)), Robert Jeyaseelan(Bristol-Myers Squibb (United States)), Barri Wautlet(Bristol-Myers Squibb (United States)), Benjamin J. Henley(Bristol-Myers Squibb (United States)), Johnni Gullo-Brown(Bristol-Myers Squibb (United States)), Veeraswamy Manne(Bristol-Myers Squibb (United States)), John T. Hunt(Bristol-Myers Squibb (United States)), Joseph Fargnoli(Bristol-Myers Squibb (United States)), R. M. Borzilleri(Bristol-Myers Squibb (United States))
Journal of Medicinal Chemistry
August 9, 2008
Cited by 123Open Access
Full Text

Abstract

Conformationally constrained 2-pyridone analogue 2 is a potent Met kinase inhibitor with an IC50 value of 1.8 nM. Further SAR of the 2-pyridone based inhibitors of Met kinase led to potent 4-pyridone and pyridine N-oxide inhibitors such as 3 and 4. The X-ray crystallographic data of the inhibitor 2 bound to the ATP binding site of Met kinase protein provided insight into the binding modes of these inhibitors, and the SAR of this series of analogues was rationalized. Many of these analogues showed potent antiproliferative activities against the Met dependent GTL-16 gastric carcinoma cell line. Compound 2 also inhibited Flt-3 and VEGFR-2 kinases with IC50 values of 4 and 27 nM, respectively. It possesses a favorable pharmacokinetic profile in mice and demonstrates significant in vivo antitumor activity in the GTL-16 human gastric carcinoma xenograft model.


Related Papers

No related papers found

Powered by citation graph analysis